+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hospital Acquired Infection Drug"

From
From
From
Hospital Infection Therapeutics Market 2024-2028 - Product Thumbnail Image

Hospital Infection Therapeutics Market 2024-2028

  • Report
  • May 2024
  • 184 Pages
  • Global
From
Vancomycin - Global Strategic Business Report - Product Thumbnail Image

Vancomycin - Global Strategic Business Report

  • Report
  • April 2025
  • 78 Pages
  • Global
From
From
From
From
  • 12 Results (Page 1 of 1)
Loading Indicator

The Hospital Acquired Infection Drug market is a subset of the Infectious Diseases Drugs market. It focuses on drugs used to treat infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). These drugs are typically antibiotics, antivirals, antifungals, and antiparasitics. They are used to treat infections that are resistant to traditional treatments, or to prevent infections in patients with weakened immune systems. The Hospital Acquired Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Johnson & Johnson, and Bayer. Show Less Read more